[Results of experimental and clinical studies of a new antileukemic drug: hexaphosphamide. Review of the literature and the author's own results].
D000380:Agranulocytosis / Q000139:chemically induced; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001388:Aziridines / Q000627:therapeutic use* / Q000633:toxicity; D001389:Azirines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007928:Lethal Dose 50; D007942:Leukemia, Experimental / Q000188:drug therapy*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D009368:Neoplasm Transplantation; D009946:Organothiophosphorus Compounds / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats
D000970:Antineoplastic Agents; D001388:Aziridines; D001389:Azirines; D009946:Organothiophosphorus Compounds; C013556:hexaphosphamide
Itogi eksperimental'nogo i klinicheskogo izucheniia novogo protivoleikoznogo preparata geksafosfamida. Obzor literatury i sobstvennye dannye.